The invasive T1 bladder tumor: Contemporary issues and rationale for radical cystectomy John P. SteinDavid F. Penson Invited Commentary 18 May 2008 Pages: 179 - 181
Possible malignancy after cytology analysis in a 45-year-old man Mark Soloway OriginalPaper 18 May 2008 Pages: 182 - 184
Rationale for statins in the chemoprevention of prostate cancer Robert J. HamiltonStephen J. Freedland OriginalPaper 18 May 2008 Pages: 189 - 196
Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors Matthew R. Smith OriginalPaper 18 May 2008 Pages: 197 - 202
Role of radical prostatectomy in the treatment of high-risk prostate cancer Ofer YossepowitchJames A. Eastham OriginalPaper 18 May 2008 Pages: 203 - 210
Watchful waiting versus active surveillance: Appropriate patient selection Marc A. Dall’EraChristopher J. Kane OriginalPaper 18 May 2008 Pages: 211 - 216
Dietary interventions in prostate cancer Wendy Demark-Wahnefried OriginalPaper 18 May 2008 Pages: 217 - 225
The use of prostate-specific antigen kinetics to stratify risk in prostate cancer Joseph Presti Jr OriginalPaper 18 May 2008 Pages: 226 - 230
Radical prostatectomy: Surgical planning, execution, and outcomes Fernando J. Bianco Jr OriginalPaper 18 May 2008 Pages: 231 - 236
Extended lymph node dissection for prostate cancer Stephan JeschkeFiona C. BurkhardUrs E. Studer OriginalPaper 18 May 2008 Pages: 237 - 242
Inflammation and prostate cancer: A focus on infections Siobhan SutcliffeElizabeth A. Platz OriginalPaper 18 May 2008 Pages: 243 - 249
Advances in robotic prostatectomy Stephen A. BoorjianMatthew T. Gettman OriginalPaper 18 May 2008 Pages: 250 - 256